Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158.4 USD | +3.30% | +8.14% | -19.73% |
Apr. 23 | Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating | MT |
Apr. 22 | Jefferies Lowers Zoetis Price Target to $200 from $220 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 28.95 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.73% | 72.39B | B+ | ||
-11.01% | 6.54B | B- | ||
+15.88% | 3.43B | B- | ||
-2.92% | 3.12B | B- | ||
-0.68% | 1.4B | - | ||
-17.27% | 1.34B | B | ||
-2.73% | 1.26B | - | ||
-14.67% | 1.12B | - | ||
-5.37% | 990M | - | ||
-24.06% | 805M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Ratings Zoetis Inc.